Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Monogue, Marguerite L ^a   Tsuji, Masakatsu ^b   Yamano, Yoshinori ^b   Echols, Roger ^b   Nicolaua, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Acinetobacter; Cefiderocol; Escherichia coli; Gram negative bacteria; Klebsiella; Pseudomonas aeruginosa; Siderophore

Indexed keywords

CEFEPIME; CEFIDEROCOL; MEROPENEM; S 649266; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; LEG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; THIGH; THIGH INFECTION; ANIMAL; DISEASE MODEL; DRUG EFFECT; GRAM NEGATIVE INFECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS; THIGH;

EID: 85032468440     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01022-17     Document Type: Article

References (24)

1. Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, Thaden JT, Stryjewski ME, van Duin D, Gram-Negative Committee of the Antibacterial Resistance Leadership Group. 2017. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 64(Suppl 1):S30–S35. https://doi.org/10.1093/cid/ciw829.
2. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. 2012. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia 16:303–307.
3. Poirel L, Nordmann P. 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12: 826–836. https://doi.org/10.1111/j.1469-0691.2006.01456.x.
4. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401.
5. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting Gram negative bacteria. J Antimicrob Chemother 71:670–677. https://doi.org/10.1093/jac/dkv402.
6. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of siderophore cephalosporin S-649266 against Enterobacteriaceae clinical isolates including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734. https://doi.org/10.1128/AAC.01695-15.
7. Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. IV. In vivo efficacy in various murine infection models, abstr F1-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
8. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V. Pharmacodynamic assessment in murine thigh infection models, abstr F1-1559, Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
9. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384 – 4386. https://doi.org/10.1128/AAC.03098-15.
10. Katsube T, Echols R, Ferreira JC, Krenz HK, Berg JK, Galloway C. 2017. Cefiderocol, a Siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584–591. https://doi.org/10.1002/jcph.841.
11. Ghazi IM, Tsuji M, Nicolau DP. 2016. Activity of S-649266 siderophore cephalosporin and comparators against Pseudomonas aeruginosa in murine thigh infection model, abstr Monday-516. Abstr American Society for Microbiology Microbe 2016, Boston, MA.
12. Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group. 2017. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72:1704–1708. https://doi.org/10.1093/jac/dkx049.
13. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother 61:e00093-17. https://doi.org/10.1128/AAC.00093-17.
14. Horiyama T, Toba S, Nakamura R. 2014. S-649266, a novel siderophore cephalosporin. VI. Magnitude of PK/PD required for efficacy in murine lung infection model, poster F1560. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
15. Horiyama T, Toba S, Nakamura R. 2014. S-649266, a novel siderophore cephalosporin. VII. Magnitude of PK/PD required for efficacy in murine thigh infection model, poster F1561. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
16. Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. 2015. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 59:7743–7752. https://doi.org/10.1128/AAC.00831-15.
17. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. 2014. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo--lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 58: 7007–7009. https://doi.org/10.1128/AAC.02662-14.
18. Crandon JL, Nicolau DP. 2015. In vivo activity of humanized cefepime and cefepime/AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother 59:2688–2694. https://doi.org/10.1128/AAC.00033-15.
19. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. 2009. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 53:1476–1481. https://doi.org/10.1128/AAC.01141-08.
20. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 51: 1481–1486. https://doi.org/10.1128/AAC.00752-06.
21. Kim A, Kuti JL, Nicolau DP. 2009. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 31:2765–2778. https://doi.org/10.1016/j.clinthera.2009.11.026.
22. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
23. Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA. 1987. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother 31:55–59. https://doi.org/10.1128/AAC.31.1.55.
24. Elkhaïli H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F. 1996. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 686:19–26. https://doi.org/10.1016/S0378-4347(96)00205-8.